Leon F Massuger
Overview
Explore the profile of Leon F Massuger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1064
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grobben Y, de Man J, van Doornmalen A, Muller M, Willemsen-Seegers N, Vu-Pham D, et al.
Front Immunol
. 2021 Feb;
11:609490.
PMID: 33584686
Indoleamine 2,3-dioxygenase (IDO1) is a key regulator of immune suppression by catalyzing the oxidation of L-tryptophan. IDO1 expression has been related to poor prognosis in several cancers and to resistance...
2.
Maas R, Hoogstad-van Evert J, Van der Meer J, Mekers V, Rezaeifard S, Korman A, et al.
Oncoimmunology
. 2020 Nov;
9(1):1843247.
PMID: 33224630
Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is...
3.
van den Brand D, van Lith S, de Jong J, Gorris M, Palacio-Castaneda V, Couwenbergh S, et al.
Cancers (Basel)
. 2020 Jul;
12(7).
PMID: 32630661
Ovarian cancer is the most lethal gynecological malignancy due to late detection associated with dissemination throughout the abdominal cavity. Targeted photodynamic therapy (tPDT) aimed at epithelial cell adhesion molecule (EpCAM),...
4.
Loopik D, Ebisch R, IntHout J, Melchers W, Massuger L, Bekkers R, et al.
Int J Cancer
. 2019 Dec;
147(3):897-900.
PMID: 31846057
Women with cervical intraepithelial neoplasia grade 3 (CIN3) have a long-lasting increased risk for noncervical high-risk human papillomavirus (hrHPV)-related (pre)malignancies. The aim of our study was to estimate this risk...
5.
Simons M, Simmer F, Bulten J, Ligtenberg M, Hollema H, van Vliet S, et al.
Mod Pathol
. 2019 Nov;
33(4):722-733.
PMID: 31695154
The origin of primary mucinous ovarian tumors is unknown. We explore the hypothesis that they originate from either Brenner tumors or teratomas and examine differences between the tumors that arise...
6.
Simons M, Bolhuis T, De Haan A, Bruggink A, Bulten J, Massuger L, et al.
Virchows Arch
. 2019 Jan;
474(3):289-296.
PMID: 30631934
Primary mucinous ovarian carcinomas (MOC) are notoriously difficult to distinguish from mucinous carcinomas metastatic to the ovary (mMC). Studies performed on small cohorts reported algorithms based on tumor size and...
7.
Yang Y, Wu L, Shu X, Lu Y, Shu X, Cai Q, et al.
Cancer Res
. 2018 Dec;
79(3):505-517.
PMID: 30559148
DNA methylation is instrumental for gene regulation. Global changes in the epigenetic landscape have been recognized as a hallmark of cancer. However, the role of DNA methylation in epithelial ovarian...
8.
Arts-De Jong M, van Westerop L, Hoogerbrugge N, Massuger L, Maas A, van Beek M, et al.
Maturitas
. 2018 Jan;
108:13-17.
PMID: 29290209
Objectives: To reduce the risk of ovarian cancer, BRCA1/2 mutation carriers are advised to undergo salpingo-oophorectomy (RRSO) around the age of 40 years. This may induce severe climacteric symptoms, potentially...
9.
Timmermans M, Schuurman M, Ho V, Massuger L, Nijman H, Van Gorp T, et al.
Gynecol Oncol
. 2017 Nov;
148(1):56-61.
PMID: 29129391
Objective: Surgical care for advanced stage epithelial ovarian cancer (EOC) patients has been centralized in the Netherlands since 2012. We evaluated whether the likelihood for patients to undergo surgery depends...
10.
Hoogstad-van Evert J, Cany J, van den Brand D, Oudenampsen M, Brock R, Torensma R, et al.
Oncoimmunology
. 2017 Sep;
6(8):e1320630.
PMID: 28919991
Adoptive transfer of allogeneic natural killer (NK) cells is an attractive therapy approach against ovarian carcinoma. Here, we evaluated the potency of highly active NK cells derived from human CD34+...